The “Iron and Phosphaturia – ExplorIRON-CKD” study was primarily designed to explore the differential effect of FDI and FCM on fibroblast growth factor 23 (FGF23) and markers relevant to hypophosphatemia and bone metabolism. Here, FGF23 is linked to chronic kidney disease.